Premium
Integrated magnetic resonance imaging and phosphorus spectroscopy of soft tissue tumors
Author(s) -
Shinkwin Michael A.,
Lenkinski Robert E.,
Daly John M.,
Zlatkin Michael B.,
Frank Thomas S.,
Holland George A.,
Kressel Herbert Y.
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910401)67:7<1849::aid-cncr2820670706>3.0.co;2-e
Subject(s) - phosphomonoesters , phosphocreatine , soft tissue , magnetic resonance imaging , medicine , phosphate , in vivo magnetic resonance spectroscopy , nuclear magnetic resonance spectroscopy , pathology , phosphorus , nuclear magnetic resonance , muscle tissue , necrosis , inorganic phosphate , nuclear medicine , energy metabolism , chemistry , radiology , biochemistry , physics , organic chemistry
Eighteen patients with soft tissue masses underwent integrated magnetic resonance imaging (MRI) and phosphorus spectroscopy ( 31 P‐MRS) to evaluate benign and malignant tumor morphology and metabolism. Spectra from soft tissue tumors had a significantly higher proportion of phosphate in the low‐energy portion of the 31 P spectrum ( P < 0.001) with a concomitant decrease in phosphocreatine ( P < 0.01) compared with 31 P spectra from normal muscle. Malignant tumors had a mean pH of 7.35 ± 0.13 which was greater than that of muscle tissue with a mean pH of 7.08 ± 0.07 ( P < 0.001). All tumors had greater relative levels of phosphomonoesters, inorganic phosphate, and phosphodiesters compared with those in muscle tissue but considerable variability among tumors was noted due to tumor size, extent of tumor necrosis, and muscle contamination. Integrated MRI/MRS studies are necessary to provide exact localization of the tumor and a more correct interpretation of the 31 P‐MRS data.